Monopar Therapeutics (MNPR) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Monopar Therapeutics.
|Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
MNPR Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for MNPR as an investment opportunity.
- MNPR has a less percent of analysts bearish on the stock than nearly 100% of all US stocks.
- MNPR has a lower variance in analysts' estimates than 4.12% of stocks in the micro market cap category.
- Monopar Therapeutics's upside potential (average analyst target price relative to current price) is greater than 95.81% of all US stocks.
- The average analyst price target of MNPR is greater than 90.02% of stocks in the micro market cap category.
- Monopar Therapeutics's percentage of analysts bullish on the stock is higher than 82.08% of all US stocks.
- The number of analysts covering the stock of MNPR is greater than 21.48% of Pharmaceutical Products stocks.
- MNPR has a lower change in bullishness amongst analysts than nearly 100% of all US stocks.
Make investment decisions regarding MNPR using the data that counts. Try POWR Ratings for free.